The analysis only uses U.S. revenue estimates generated from TG-1101 in relapsed and refractory NHL and CLL patient populations, as well as its current cash flow position.
FORBES: Don't Be Surprised If Underpriced Small-Cap Biotechs Catch Investors' Eye Once Again